BetterLife Pharma Launches $500,000 Private Placement to Advance LSD-Derived Neurology Drug

An update from BetterLife Pharma ( (TSE:BETR) ) is now available.

BetterLife Pharma announced plans for a non-brokered private placement of up to $500,000, offering units at $0.07 each, with each unit comprising one common share and a warrant exercisable at $0.10 for two years. The financing, expected to close around April 17, 2026 subject to regulatory approvals and resale restrictions, is aimed at funding further development of its lead compound BETR-001 and supporting general working capital, underscoring the company’s reliance on equity markets to advance its preclinical pipeline in the competitive neurological therapeutics space.

The structure and modest size of the raise highlight BetterLife’s early-stage status and focus on non-hallucinogenic LSD-based treatments, a niche within mental health biotech that seeks to capture interest in psychedelic-adjacent therapies without the regulatory burden of controlled substances. Investors will be watching how efficiently the proceeds accelerate BETR-001’s progression toward clinical trials and whether strategic options for its separate antiviral candidate can unlock additional value or partnerships.

The most recent analyst rating on (TSE:BETR) stock is a Hold with a C$0.09 price target. To see the full list of analyst forecasts on BetterLife Pharma stock, see the TSE:BETR Stock Forecast page.

Spark’s Take on BETR Stock

According to Spark, TipRanks’ AI Analyst, BETR is a Neutral.

The score is held back primarily by fragile financials (no revenue, ongoing losses, negative equity), partially offset by improving recent cash burn/loss trends. Technicals are the main positive with clear upward price momentum, while valuation provides limited support due to negative earnings and no dividend.

To see Spark’s full report on BETR stock, click here.

More about BetterLife Pharma

BetterLife Pharma Inc. is an emerging biotechnology company developing and commercializing non-hallucinogenic, non-controlled LSD derivatives for neurological and mental disorders. Its lead candidate, BETR-001, is in preclinical and IND-enabling studies, supported by a synthesis patent and pending composition and use patents potentially extending protection to around 2042, and the firm also holds a drug candidate for viral infections.

Average Trading Volume: 108,654

Technical Sentiment Signal: Sell

Current Market Cap: C$9.87M

For an in-depth examination of BETR stock, go to TipRanks’ Overview page.